These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 32810332)
1. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer. Wang Y; Zhang M; Wang Z; Guo W; Yang D Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332 [TBL] [Abstract][Full Text] [Related]
2. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Wang Z; Yang B; Zhang M; Guo W; Wu Z; Wang Y; Jia L; Li S; ; Xie W; Yang D Cancer Cell; 2018 Apr; 33(4):706-720.e9. PubMed ID: 29622465 [TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. Li Y; Cai Q; Li W; Feng F; Yang L Biochem Biophys Res Commun; 2018 Oct; 504(4):654-659. PubMed ID: 30205958 [TBL] [Abstract][Full Text] [Related]
4. Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer. Wang H; Huang F; Zhang Z; Wang P; Luo Y; Li H; Li N; Wang J; Zhou J; Wang Y; Li S Int J Biol Sci; 2019; 15(5):929-941. PubMed ID: 31182914 [TBL] [Abstract][Full Text] [Related]
5. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA EPIC1 promotes human lung cancer cell growth. Zhang B; Lu HY; Xia YH; Jiang AG; Lv YX Biochem Biophys Res Commun; 2018 Sep; 503(3):1342-1348. PubMed ID: 30029875 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280 [TBL] [Abstract][Full Text] [Related]
8. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457 [TBL] [Abstract][Full Text] [Related]
9. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity. Martin J; Masri J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Anderson L; Bashir T; Bernath A; Lichtenstein A; Gera J J Biol Chem; 2011 May; 286(18):16402-13. PubMed ID: 21454539 [TBL] [Abstract][Full Text] [Related]
10. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction. Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905 [TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway. Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851 [TBL] [Abstract][Full Text] [Related]
12. LncRNA EPIC1 protects human osteoblasts from dexamethasone-induced cell death. Zhang XY; Shan HJ; Zhang P; She C; Zhou XZ Biochem Biophys Res Commun; 2018 Sep; 503(4):2255-2262. PubMed ID: 29959919 [TBL] [Abstract][Full Text] [Related]
13. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation. Vartanian R; Masri J; Martin J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Gera J Mol Cancer Res; 2011 Jan; 9(1):115-30. PubMed ID: 21135252 [TBL] [Abstract][Full Text] [Related]
14. A nuclear lncRNA Linc00839 as a Myc target to promote breast cancer chemoresistance via PI3K/AKT signaling pathway. Chen Q; Shen H; Zhu X; Liu Y; Yang H; Chen H; Xiong S; Chi H; Xu W Cancer Sci; 2020 Sep; 111(9):3279-3291. PubMed ID: 32619088 [TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma. Yu VZ; Ko JMY; Ning L; Dai W; Law S; Lung ML Cancer Lett; 2019 Oct; 461():56-64. PubMed ID: 31319137 [TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis. Wang J; Yang X; Li R; Wang L; Gu Y; Zhao Y; Huang KH; Cheng T; Yuan Y; Gao S Oncol Rep; 2018 Nov; 40(5):2814-2825. PubMed ID: 30132573 [TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Wu C; Luo J Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938 [TBL] [Abstract][Full Text] [Related]
18. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Mi W; Ye Q; Liu S; She QB Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827 [TBL] [Abstract][Full Text] [Related]
19. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X Oncotarget; 2015 Sep; 6(28):25381-9. PubMed ID: 26299803 [TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop. Zhang X; Niu W; Mu M; Hu S; Niu C J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]